Inventors:
Darby Schmidt - Arlington MA, US
Subharekha Raghavan - Teaneck NJ, US
John Stelmach - Westfield NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan Groeper - Metuchen NJ, US
Linda Brockunier - Orange NJ, US
Keith Rosauer - Laurence Harbor NJ, US
Hong Shen - West Windsor NJ, US
Rui Liang - East Brunswick NJ, US
International Classification:
C07D 403/14
A61K 31/506
C07D 471/04
C07D 401/14
C07D 413/14
A61K 31/5377
C07D 417/14
C07D 403/04
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 11/00
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 7/10
A61P 3/00
A61P 3/06
C07D 487/04
US Classification:
5142345, 544236, 514248, 544328, 514256, 544324, 514275, 544296, 544122, 544295, 51425505
Abstract:
The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
